MCID: ATY042
MIFTS: 48

Atypical Chronic Myeloid Leukemia

Categories: Cancer diseases, Blood diseases, Rare diseases, Immune diseases

Aliases & Classifications for Atypical Chronic Myeloid Leukemia

MalaCards integrated aliases for Atypical Chronic Myeloid Leukemia:

Name: Atypical Chronic Myeloid Leukemia 12 12 56 14
Subacute Myeloid Leukemia 12 56 14
Leukemia, Myeloid, Chronic, Atypical, Bcr-Abl Negative 42 69
Atypical Chronic Myeloid Leukemia Bcr-Abl1 Negative 12
Subacute Granulocytic Leukemia 12
Subacute Myelogenous Leukemia 12
Atypical Cml 12
Acml 12

Characteristics:

Orphanet epidemiological data:

56
atypical chronic myeloid leukemia
Age of onset: Adult;

Classifications:



External Ids:

Disease Ontology 12 DOID:0060597 DOID:8747
ICD10 33 C92.2
MeSH 42 D054438
NCIt 47 C3519
SNOMED-CT 64 95278004
Orphanet 56 ORPHA98824
MESH via Orphanet 43 D054438
UMLS via Orphanet 70 C0349640 C1292772
ICD10 via Orphanet 34 C92.2

Summaries for Atypical Chronic Myeloid Leukemia

Disease Ontology : 12 A myelodysplastic myeloproliferative neoplasm characterized by the principal involvement of the neutrophil series with leukocytosis and multilineage dysplasia. The neoplastic cells do not have a Philadelphia chromosome or the BCR/ABL fusion gene.

MalaCards based summary : Atypical Chronic Myeloid Leukemia, also known as subacute myeloid leukemia, is related to leukemia, chronic myeloid, somatic and myelodysplastic myeloproliferative cancer. An important gene associated with Atypical Chronic Myeloid Leukemia is CSF3R (Colony Stimulating Factor 3 Receptor), and among its related pathways/superpathways are Akt Signaling and Cytokine Signaling in Immune system. The drugs Busulfan and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are Increased shRNA abundance (Z-score > 2) and cellular

Wikipedia : 72 Atypical chronic myeloid leukemia (aCML) is a type of leukemia. It is a heterogeneous disorder belonging... more...

Related Diseases for Atypical Chronic Myeloid Leukemia

Diseases related to Atypical Chronic Myeloid Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 42)
id Related Disease Score Top Affiliating Genes
1 leukemia, chronic myeloid, somatic 11.1
2 myelodysplastic myeloproliferative cancer 11.0
3 leukemia 10.5
4 myeloid leukemia 10.5
5 split hand/foot malformation x-linked 10.3 JAK2 SETBP1
6 primary cutaneous peripheral t-cell lymphoma not otherwise specified 10.2 ASXL1 SETBP1
7 movement disease 10.1 ASXL1 PDGFRA
8 chronic myelomonocytic leukemia 10.1
9 dyserythropoietic anemia and thrombocytopenia 10.0 JAK2 RUNX1
10 ovarian large-cell neuroendocrine carcinoma 10.0 FGFR1 PDGFRA
11 thrombocytopenia-absent radius syndrome 10.0 FGFR1 JAK2
12 wilms tumor 6 9.9 PDGFRA PDGFRB
13 desmoplastic small round cell tumor 9.9 PDGFRA PDGFRB
14 chronic neutrophilic leukemia 9.9
15 moved to 122000 9.8 PDGFRA PDGFRB
16 budd-chiari syndrome 9.8 JAK2 PDGFRA
17 extraosseous osteosarcoma 9.7 PDGFRA PDGFRB
18 myeloproliferative neoplasm 9.7
19 tetrasomy 21 9.7
20 malignant epithelioid hemangioendothelioma 9.7 ASXL1 CSF3R SETBP1
21 postsynaptic congenital myasthenic syndromes 9.6 ASXL1 JAK2 RUNX1
22 primary bone lymphoma 9.6 FGFR1 PDGFRA PDGFRB
23 hypereosinophilic syndrome, idiopathic, resistant to imatinib 9.6 PDGFRA PDGFRB
24 alopecia antibody deficiency 9.5 FGFR1 PDGFRA PDGFRB
25 18p deletion syndrome 9.5 FGFR1 PDGFRA PDGFRB
26 benign mammary dysplasia 9.4 CSF3R PDGFRA PDGFRB
27 glomus tympanicum tumor 9.4 FGFR1 PDGFRA PDGFRB
28 cask-related intellectual disability 9.4 FGFR1 PDGFRB RUNX1
29 hemolytic anemia 9.4 JAK2 PDGFRB RUNX1
30 kala-azar 1 9.3 FGFR1 PDGFRA PDGFRB
31 nephrolithiasis 9.3 ASXL1 CSF3R JAK2 SETBP1
32 myeloid neoplasms associated with pdgfrb rearrangement 9.2 FGFR1 JAK2 PDGFRA PDGFRB
33 temporal lobe epilepsy 9.2 FGFR1 JAK2 PDGFRA PDGFRB
34 focal epilepsy 9.1 FGFR1 JAK2 PDGFRA PDGFRB
35 nephronophthisis 15 9.1 JAK2 PDGFRB RUNX1 SETBP1
36 thrombocythemia 3 9.1 CSF3R JAK2 PDGFRA PDGFRB
37 peroxisome biogenesis disorder 7a 8.7 JAK2 PDGFRA PDGFRB RUNX1 SETBP1
38 chronic venous leg ulcers 8.5 ASXL1 JAK2 PDGFRB RUNX1 SETBP1
39 cranioectodermal dysplasia 1 8.3 ASXL1 CSF3R FGFR1 JAK2 RUNX1 SETBP1
40 nelson syndrome 8.1 CSF3R FGFR1 JAK2 PDGFRA PDGFRB RUNX1
41 leukemia, acute myeloid 8.0 ASXL1 CSF3R JAK2 PDGFRB RUNX1 SETBP1
42 fetal nicotine spectrum disorder 6.8 ASXL1 CSF3R FGFR1 JAK2 PCM1 PDGFRA

Graphical network of the top 20 diseases related to Atypical Chronic Myeloid Leukemia:



Diseases related to Atypical Chronic Myeloid Leukemia

Symptoms & Phenotypes for Atypical Chronic Myeloid Leukemia

GenomeRNAi Phenotypes related to Atypical Chronic Myeloid Leukemia according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-107 9.72 CSF3R
2 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.72 SETBP1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.72 CSF3R
4 Increased shRNA abundance (Z-score > 2) GR00366-A-129 9.72 PDGFRA
5 Increased shRNA abundance (Z-score > 2) GR00366-A-136 9.72 CSF3R
6 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.72 SETBP1 CSF3R PDGFRA
7 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.72 SETBP1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-164 9.72 SETBP1 CSF3R
9 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.72 CSF3R
10 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.72 SETBP1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-185 9.72 SETBP1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.72 SETBP1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-194 9.72 SETBP1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-197 9.72 CSF3R
15 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.72 PDGFRA
16 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.72 PDGFRA
17 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.72 PDGFRA
18 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.72 CSF3R
19 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.72 PDGFRA
20 Increased shRNA abundance (Z-score > 2) GR00366-A-8 9.72 SETBP1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.72 SETBP1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.72 SETBP1

MGI Mouse Phenotypes related to Atypical Chronic Myeloid Leukemia:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.91 ASXL1 CSF3R FGFR1 JAK2 PDGFRA PDGFRB
2 endocrine/exocrine gland MP:0005379 9.8 ASXL1 FGFR1 JAK2 PDGFRA PDGFRB RUNX1
3 hematopoietic system MP:0005397 9.8 ASXL1 CSF3R FGFR1 JAK2 PDGFRA PDGFRB
4 immune system MP:0005387 9.7 ASXL1 CSF3R FGFR1 JAK2 PDGFRA PDGFRB
5 mortality/aging MP:0010768 9.56 SETBP1 ASXL1 CSF3R FGFR1 JAK2 PDGFRA
6 skeleton MP:0005390 9.1 ASXL1 FGFR1 JAK2 PDGFRA PDGFRB RUNX1

Drugs & Therapeutics for Atypical Chronic Myeloid Leukemia

Drugs for Atypical Chronic Myeloid Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 307)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1 55-98-1 2478
2
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
3
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1 147-94-4 6253
4
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
5
Hydroxyurea Approved Phase 3,Phase 2 127-07-1 3657
6
Idarubicin Approved Phase 3 58957-92-9 42890
7
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
8
Azacitidine Approved, Investigational Phase 3,Phase 1 320-67-2 9444
9
Decitabine Approved, Investigational Phase 3,Phase 1 2353-33-5 451668
10
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
11
Fludarabine Approved Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
12
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
13
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2,Phase 1 128794-94-5 5281078
14
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1 24280-93-1 446541
15
Daunorubicin Approved Phase 3 20830-81-3 30323
16
Mitoxantrone Approved, Investigational Phase 3,Phase 2 65271-80-9 4212
17
Thioguanine Approved Phase 3 154-42-7 2723601
18
Ephedrine Approved Phase 3 299-42-3 9294
19
Pseudoephedrine Approved Phase 3 90-82-4 7028
20
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
21
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 498142 38904
22
Melphalan Approved Phase 2, Phase 3,Phase 1 148-82-3 4053 460612
23 Thiotepa Approved Phase 2, Phase 3,Phase 1 52-24-4 5453
24
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
25
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
26
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
27
Norgestimate Approved Phase 3 35189-28-7 6540478
28
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 1 302-79-4 5538
29
Ginseng Approved, Nutraceutical Phase 3 50647-08-0
30 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
31 Alkylating Agents Phase 3,Phase 2,Phase 1
32 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
33 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
34 Anti-Infective Agents Phase 3,Phase 2,Phase 1
35 Antimetabolites Phase 3,Phase 2,Phase 1
36 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
37 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
38 Antirheumatic Agents Phase 3,Phase 2,Phase 1
39 Antiviral Agents Phase 3,Phase 2,Phase 1
40 Etoposide phosphate Phase 3,Phase 2,Phase 1
41 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
42 Interferon-alpha Phase 3,Phase 2
43 interferons Phase 3,Phase 2
44 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1,Early Phase 1
45 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
46 6-Mercaptopurine Phase 3
47 Analgesics Phase 3,Phase 2,Phase 1
48 Anesthetics Phase 3
49 Anesthetics, Dissociative Phase 3
50 Anesthetics, General Phase 3

Interventional clinical trials:

(show top 50) (show all 207)

id Name Status NCT ID Phase Drugs
1 Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia Unknown status NCT00025402 Phase 3 busulfan;cyclophosphamide;cytarabine;etoposide;hydroxyurea;idarubicin
2 Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic Syndrome Unknown status NCT00047268 Phase 3 cytarabine;mercaptopurine
3 Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome Unknown status NCT00043134 Phase 3 decitabine
4 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
5 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
6 Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
7 Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia Completed NCT00005863 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;tretinoin
8 Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer Completed NCT00265837 Phase 3
9 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
10 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
11 A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families Completed NCT00782145 Phase 3
12 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
13 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
14 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
15 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
16 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
17 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
18 Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD) Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
19 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
20 Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer Unknown status NCT00044954 Phase 2 cyclosporine;fludarabine phosphate;mycophenolate mofetil
21 Tipifarnib in Treating Patients With Myeloproliferative Disorders Unknown status NCT00005846 Phase 1, Phase 2 tipifarnib
22 Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes Unknown status NCT00020969 Phase 2 arsenic trioxide
23 Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia Unknown status NCT00008164 Phase 2
24 Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation Unknown status NCT00036712 Phase 2
25 Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia Completed NCT00079313 Phase 2 Imatinib
26 Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia Completed NCT00002598 Phase 2 cyclophosphamide;cytarabine;etoposide;methotrexate;mitoxantrone hydrochloride
27 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia Completed NCT00381550 Phase 2 fludarabine phosphate;triapine
28 Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders Completed NCT02210858 Phase 1, Phase 2 Tipifarnib
29 Monoclonal Antibody Plus Interleukin-2 in Treating Patients With Leukemia or Lymphoma Completed NCT00002681 Phase 1, Phase 2
30 Combination Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloproliferative Disorders Completed NCT00002792 Phase 2 busulfan;cyclophosphamide;cyclosporine;methotrexate;tacrolimus
31 Anti-Thymocyte Globulin and Etanercept in Treating Patients With Myelodysplastic Syndromes Completed NCT00217386 Phase 2
32 Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) Completed NCT00255346 Phase 2 Dasatinib (BMS-354825)
33 Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
34 Fludarabine/Carboplatin/Topotecan w/Thalidomide for Relapsed/Refractory AML, CML and MDS Completed NCT00053287 Phase 2 carboplatin;fludarabine phosphate;thalidomide;topotecan hydrochloride
35 Doxercalciferol in Treating Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Completed NCT00052832 Phase 2
36 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant Completed NCT00795769 Phase 2 ondansetron
37 Busulfan and Cyclophosphamide Followed by Bone Marrow Transplantation in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Completed NCT00004896 Phase 2 busulfan;cyclophosphamide
38 Chemotherapy Plus Bone Marrow Transplantation and Filgrastim in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Completed NCT00004899 Phase 2 busulfan;etoposide
39 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
40 Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Myeloproliferative Disorder Completed NCT00049634 Phase 1, Phase 2 busulfan;cyclophosphamide;cyclosporine;methotrexate
41 Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes Completed NCT00093366 Phase 1, Phase 2 arsenic trioxide
42 VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia Completed NCT00083187 Phase 2 hydroxyurea;laromustine
43 Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia or Lymphoma Completed NCT00047021 Phase 2 cytarabine;mitoxantrone hydrochloride
44 FR901228 in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Non-Hodgkin's Lymphoma Completed NCT00042822 Phase 2 romidepsin
45 Cholecalciferol in Treating Patients With Myelodysplastic Syndrome Completed NCT00068276 Phase 2
46 Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders Completed NCT00055653 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;melphalan;methylprednisolone
47 T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia Completed NCT00002718 Phase 2 cyclophosphamide;cytarabine;methylprednisolone;thiotepa
48 Bone Marrow Transplant Plus Cyclophosphamide and Total-Body Irradiation in Treating Patients With Hematologic Cancer Completed NCT00002809 Phase 2 cyclophosphamide;methotrexate;tacrolimus
49 Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder Completed NCT00274820 Phase 2 arsenic trioxide;dexamethasone;thalidomide
50 Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00089037 Phase 1, Phase 2 methotrexate;sirolimus;tacrolimus

Search NIH Clinical Center for Atypical Chronic Myeloid Leukemia

Cochrane evidence based reviews: leukemia, myeloid, chronic, atypical, bcr-abl negative

Genetic Tests for Atypical Chronic Myeloid Leukemia

Anatomical Context for Atypical Chronic Myeloid Leukemia

MalaCards organs/tissues related to Atypical Chronic Myeloid Leukemia:

39
Myeloid, Bone, Bone Marrow, Neutrophil, Liver, Breast, T Cells

Publications for Atypical Chronic Myeloid Leukemia

Articles related to Atypical Chronic Myeloid Leukemia:

(show all 38)
id Title Authors Year
1
Atypical chronic myeloid leukemia with isochromosome (X)(p10): A case report. ( 28927137 )
2017
2
Atypical chronic myeloid leukemia in a German Shepherd Dog. ( 28205462 )
2017
3
Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia. ( 28314085 )
2017
4
Decitabine for the treatment of atypical chronic myeloid leukemia: A report of two cases. ( 26870268 )
2016
5
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, in a 5-Month Baby - ARare Presentation. ( 28666496 )
2016
6
Leukemia cutis presenting as scaly plaques in a Christmas tree distribution in a patient with atypical chronic myeloid leukemia. ( 27853001 )
2016
7
Activity of single-agent decitabine in atypical chronic myeloid leukemia. ( 26378157 )
2016
8
Atypical Chronic Myeloid Leukemia in Two Pediatric Patients. ( 26274939 )
2016
9
How I treat atypical chronic myeloid leukemia. ( 27899359 )
2016
10
Centromeric fragment of chromosome 7 in atypical chronic myeloid leukemia with the SET binding protein 1 gene mutation. ( 24991718 )
2015
11
Evaluation of a father and son with atypical chronic myeloid leukemia with SETBP1 mutations and a review of the literature. ( 26017341 )
2015
12
A novel mutation of SETBP1 in atypical chronic myeloid leukemia transformed from acute myelomonocytic leukemia. ( 26185647 )
2015
13
Efficacy and side-effects of decitabine in treatment of atypical chronic myeloid leukemia. ( 25426665 )
2015
14
Atypical chronic myeloid leukemia with concomitant CSF3R T618I and SETBP1 mutations unresponsive to the JAK inhibitor ruxolitinib. ( 25491280 )
2015
15
Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. ( 25343957 )
2015
16
Durable Disease Control with MEK Inhibition in a Patient with NRAS-mutated Atypical Chronic Myeloid Leukemia. ( 26870618 )
2015
17
Transformation from atypical chronic myeloid leukemia to chronic myelomonocytic leukemia as progression of myeloid neoplasm with platelet-derived growth factor A9 rearrangement. ( 26881541 )
2015
18
Molecular genetics of chronic neutrophilic leukemia, chronic myelomonocytic leukemia and atypical chronic myeloid leukemia. ( 25498990 )
2014
19
Establishment and characterization of a rare atypical chronic myeloid leukemia cell line NT-1. ( 25012564 )
2014
20
Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia. ( 25180155 )
2014
21
Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia. ( 25239264 )
2014
22
Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. ( 24627528 )
2014
23
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. ( 23222956 )
2013
24
Successful transplantation of ethnically mismatched cord blood in a boy with atypical chronic myeloid leukemia. ( 23264127 )
2013
25
Atypical chronic myeloid leukemia with t(9;22)(p24,11.2), a BCR-JAK2 fusion gene. ( 23904814 )
2013
26
Atypical chronic myeloid leukemia harboring NUP98-HOXA9. ( 23754767 )
2013
27
A BCR-JAK2 fusion gene from ins(22;9)(q11;p13p24) in a patient with atypical chronic myeloid leukemia. ( 23432689 )
2013
28
Chronic myelomonocytic leukemia and atypical chronic myeloid leukemia: novel pathogenetic lesions. ( 22289493 )
2012
29
t(3;21)(q22;q22) leading to truncation of the RYK gene in atypical chronic myeloid leukemia. ( 19168282 )
2009
30
JAK2 mutation and atypical chronic myeloid leukemia. ( 19427035 )
2009
31
The role of peripheral blood, bone marrow aspirate and especially bone marrow trephine biopsy in distinguishing atypical chronic myeloid leukemia from chronic granulocytic leukemia and chronic myelomonocytic leukemia. ( 19500135 )
2009
32
Atypical chronic myeloid leukemia as defined in the WHO classification is a JAK2 V617F negative neoplasm. ( 18555525 )
2008
33
Molecular and cytogenetic characterization of a novel translocation t(4;22) involving the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with atypical chronic myeloid leukemia. ( 15034867 )
2004
34
Two clonal occurrences of tetrasomy 21 in an atypical chronic myeloid leukemia with wild-type RUNX1 alleles. Additional support for a gene dosage effect of chromosome 21 or RUNX1 in leukemia. ( 15339695 )
2004
35
Imatinib mesylate elicits positive clinical response in atypical chronic myeloid leukemia involving the platelet-derived growth factor receptor beta. ( 14504072 )
2003
36
Translocation t(9;22) (p23;q11) in atypical chronic myeloid leukemia (aCML) presenting osteolytic lesions. ( 12463598 )
2002
37
A diagnostic dilemma: chronic myelomonocytic leukemia versus atypical chronic myeloid leukemia. A case report and review of the literature. ( 9401502 )
1997
38
[Atypical chronic myeloid leukemia with polymorphism of the BCR gene]. ( 1687492 )
1991

Variations for Atypical Chronic Myeloid Leukemia

Expression for Atypical Chronic Myeloid Leukemia

Search GEO for disease gene expression data for Atypical Chronic Myeloid Leukemia.

Pathways for Atypical Chronic Myeloid Leukemia

Pathways related to Atypical Chronic Myeloid Leukemia according to GeneCards Suite gene sharing:

(show all 19)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.08 CSF3R FGFR1 JAK2 PDGFRA PDGFRB
2
Show member pathways
13.03 CSF3R FGFR1 JAK2 PDGFRA PDGFRB
3
Show member pathways
12.94 CSF3R FGFR1 JAK2 PDGFRA PDGFRB
4
Show member pathways
12.74 FGFR1 JAK2 PDGFRA PDGFRB
5
Show member pathways
12.55 FGFR1 JAK2 PDGFRA PDGFRB
6 12.25 CSF3R FGFR1 JAK2 PDGFRA PDGFRB
7
Show member pathways
12.21 FGFR1 PDGFRA PDGFRB
8
Show member pathways
12.18 FGFR1 JAK2 PDGFRA PDGFRB RUNX1
9
Show member pathways
12.15 FGFR1 PDGFRA PDGFRB
10
Show member pathways
11.88 CSF3R FGFR1 PDGFRA PDGFRB
11 11.62 CSF3R FGFR1 PDGFRA PDGFRB RUNX1
12 11.52 FGFR1 PDGFRA PDGFRB
13 11.45 FGFR1 PDGFRA PDGFRB
14 11.41 FGFR1 JAK2 PDGFRA PDGFRB
15 11.27 JAK2 PDGFRB
16 11.25 FGFR1 PDGFRA PDGFRB
17 10.99 FGFR1 PDGFRA PDGFRB
18 10.86 PDGFRA PDGFRB
19 10.6 PDGFRA PDGFRB

GO Terms for Atypical Chronic Myeloid Leukemia

Cellular components related to Atypical Chronic Myeloid Leukemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 intrinsic component of plasma membrane GO:0031226 8.62 PDGFRA PDGFRB

Biological processes related to Atypical Chronic Myeloid Leukemia according to GeneCards Suite gene sharing:

(show all 27)
id Name GO ID Score Top Affiliating Genes
1 phosphorylation GO:0016310 9.91 FGFR1 JAK2 PDGFRA PDGFRB
2 protein phosphorylation GO:0006468 9.91 FGFR1 JAK2 PDGFRA PDGFRB
3 positive regulation of GTPase activity GO:0043547 9.89 FGFR1 JAK2 PDGFRA PDGFRB
4 positive regulation of cell proliferation GO:0008284 9.88 FGFR1 JAK2 PDGFRA PDGFRB
5 positive regulation of cell migration GO:0030335 9.76 JAK2 PDGFRA PDGFRB
6 MAPK cascade GO:0000165 9.76 FGFR1 JAK2 PDGFRA PDGFRB
7 phosphatidylinositol-mediated signaling GO:0048015 9.72 FGFR1 PDGFRA PDGFRB
8 phosphatidylinositol phosphorylation GO:0046854 9.7 FGFR1 PDGFRA PDGFRB
9 regulation of phosphatidylinositol 3-kinase signaling GO:0014066 9.65 FGFR1 PDGFRA PDGFRB
10 positive regulation of fibroblast proliferation GO:0048146 9.63 PDGFRA PDGFRB
11 response to retinoic acid GO:0032526 9.62 ASXL1 PDGFRB
12 chondrocyte differentiation GO:0002062 9.62 FGFR1 RUNX1
13 protein autophosphorylation GO:0046777 9.62 FGFR1 JAK2 PDGFRA PDGFRB
14 cell migration GO:0016477 9.61 FGFR1 JAK2 PDGFRB
15 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.6 PDGFRA PDGFRB
16 positive regulation of phosphoprotein phosphatase activity GO:0032516 9.57 JAK2 PDGFRB
17 peptidyl-tyrosine phosphorylation GO:0018108 9.56 FGFR1 JAK2 PDGFRA PDGFRB
18 cardiac myofibril assembly GO:0055003 9.54 PDGFRA PDGFRB
19 retina vasculature development in camera-type eye GO:0061298 9.51 PDGFRA PDGFRB
20 negative regulation of platelet-derived growth factor receptor-beta signaling pathway GO:2000587 9.49 PDGFRA PDGFRB
21 metanephric glomerular capillary formation GO:0072277 9.4 PDGFRA PDGFRB
22 positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway GO:0038091 9.37 PDGFRA PDGFRB
23 skeletal system morphogenesis GO:0048705 9.33 FGFR1
24 platelet-derived growth factor receptor signaling pathway GO:0048008 9.33 JAK2 PDGFRA PDGFRB
25 regulation of myeloid cell differentiation GO:0045637 9.26 CSF3R
26 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.26 FGFR1 JAK2 PDGFRA PDGFRB
27 positive regulation of phospholipase C activity GO:0010863 8.8 FGFR1 PDGFRA PDGFRB

Molecular functions related to Atypical Chronic Myeloid Leukemia according to GeneCards Suite gene sharing:

(show all 12)
id Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.91 FGFR1 JAK2 PDGFRA PDGFRB RUNX1
2 kinase activity GO:0016301 9.8 FGFR1 JAK2 PDGFRA PDGFRB
3 protein kinase activity GO:0004672 9.78 FGFR1 JAK2 PDGFRA PDGFRB
4 nucleotide binding GO:0000166 9.71 FGFR1 JAK2 PDGFRA PDGFRB
5 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.5 FGFR1 PDGFRA PDGFRB
6 phosphatidylinositol 3-kinase binding GO:0043548 9.46 JAK2 PDGFRB
7 platelet-derived growth factor receptor binding GO:0005161 9.43 PDGFRA PDGFRB
8 platelet-derived growth factor binding GO:0048407 9.37 PDGFRA PDGFRB
9 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.33 FGFR1 PDGFRA PDGFRB
10 vascular endothelial growth factor binding GO:0038085 9.26 PDGFRA PDGFRB
11 protein tyrosine kinase activity GO:0004713 9.26 FGFR1 JAK2 PDGFRA PDGFRB
12 Ras guanyl-nucleotide exchange factor activity GO:0005088 8.92 FGFR1 JAK2 PDGFRA PDGFRB

Sources for Atypical Chronic Myeloid Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....